ReviewTherapeutic advances in endocrinology and metabolism2022
Recent advancement in the treatment of boys and adolescents with hypogonadism.
Review in Therapeutic advances in endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Effects of testosterone and high-dose anabolic steroids on orthodontic-induced bone remodeling and root resorption: An animal study.Journal of periodontology · 2026Article
- LHCGR phamacodynamic effects during follicular maturation.Frontiers in endocrinology · 2026Review
- Review
- Construction of human pluripotent stem cell-derived testicular organoids and their use as humanized testis models for evaluating the effects of semaglutide.Theranostics · 2025Article
- Pharmaceutical Pollutants: Ecotoxicological Impacts and the Use of Agro-Industrial Waste for Their Removal from Aquatic Environments.Journal of xenobiotics · 2024Review
- Current landscape of fertility induction in males with congenital hypogonadotropic hypogonadism.Annals of the New York Academy of Sciences · 2024Review
- Markers of Fertility in Adolescents With Chronic Endocrinopathies at Transition From Paediatric to Adult Care.Endocrinology, diabetes & metabolism · 2024Article
- Microphallus early management in infancy saves adulthood sensual life: A comprehensive review.World journal of clinical pediatrics · 2024Review
- Hormone Regulation in Testicular Development and Function.International journal of molecular sciences · 2024Review
- Bibliometric analysis of scientific publications on cryptorchidism: Research hotspots and trends between 2000 and 2022.Heliyon · 2023Article
- Management of Neonatal Isolated and Combined Growth Hormone Deficiency: Current Status.International journal of molecular sciences · 2023Review
- Delayed Puberty.Indian journal of pediatrics · 2023Review
- Testosterone propionate andInternational journal of reproductive biomedicine · 2023Article
- Effect of Recombinant Gonadotropin on Testicular Function and Testicular Sperm Extraction in Five Cases ofFrontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical manifestations and the need for treatment varies according to age in males with hypogonadism. Early foetal-onset hypogonadism results in disorders of sex development (DSD) presenting with undervirilised genitalia whereas hypogonadism established later in foetal life presents with micropenis, cryptorchidism and/or micro-orchidism. After the period of neonatal activation of the gonadal axis has waned, the diagnosis of hypogonadism is challenging because androgen deficiency is not apparent until the age of puberty. Then, the differential diagnosis between constitutional delay of puberty and central hypogonadism may be difficult. During infancy and childhood, treatment is usually sought because of micropenis and/or cryptorchidism, whereas lack of pubertal development and relative short stature are the main complaints in teenagers. Testosterone therapy has been the standard, although off-label, in the vast majority of cases. However, more recently alternative therapies have been tested: aromatase inhibitors to induce the hypothalamic-pituitary-testicular axis in boys with constitutional delay of puberty and replacement with GnRH or gonadotrophins in those with central hypogonadism. Furthermore, follicle-stimulating hormone (FSH) priming prior to hCG or luteinizing hormone (LH) treatment seems effective to induce an enhanced testicular enlargement. Although the rationale for gonadotrophin or GnRH treatment is based on mimicking normal physiology, long-term results are still needed to assess their impact on adult fertility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.